Inhibition of cell growth by N-(phosphonacetyl)-L-aspartate in human and murine cells in vitro.

Abstract

Two murine cell lines, L1210 leukemia (T-cell) and B16 melanoma, and 3 human cell lines, CCRF-CEM leukemia (T-cell), NC37 lymphoblasts (B-cell) and IPC-48 melanoma were compared with respect to sensitivity to N-(phosphonacetyl)-L-aspartate (PALA), growth rate and aspartate transcarbamylase activity. No correlation between drug sensitivity and growth rate was found. The melanoma cell lines were more sensitive to PALA than were the lymphocytic cell lines. The 2 T-cell leukemia lines had similar sensitivities to PALA while the B-lymphoblasts were more resistant at 10(-3) M PALA and less resistant at 10(-4) M PALA than were L1210 and CCRF-CEM cells. Aspartate transcarbamylase activity was similar among the 2 melanoma cell lines and among the 3 lymphocytic cell lines and was 2-fold higher in the latter.

• Authors: A Leyva, H Appel, P Smith, J Lankelma, H M Pinedo
• Journal: Cancer letters (Cancer Lett) Vol. 12 Issue 1-2 Pg. 169-73 (Mar 1981) ISSN: 0304-3835 [Print] Ireland
• PMID: 7273001 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antineoplastic Agents
• Organophosphorus Compounds
• Aspartic Acid
• sparfosic acid
• Aspartate Carbamoyltransferase
• Phosphonoacetic Acid

Topics

• Animals
• Antineoplastic Agents (pharmacology)
• Aspartate Carbamoyltransferase (analysis)
• Aspartic Acid (analogs & derivatives, pharmacology)
• Cell Division (drug effects)
• Cell Line
• Humans
• Leukemia (drug therapy)
• Melanoma (drug therapy)
• Mice
• Neoplasms (drug therapy, enzymology, pathology)
• Organophosphorus Compounds (pharmacology)
• Phosphonoacetic Acid (analogs & derivatives, pharmacology)